Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis
European Respiratory Journal · 2025
DOI: 10.1183/13993003.01574-2024 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, 2025. Verfasst von Ran Guo und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, The University of Hong Kong Shen Zhen Hospital, Shen Zhen, China. Hauptthemen laut MEDLINE: Bronchiectasis, Macrolides, Anti-Bacterial Agents, Cardiovascular Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanming Project of Medicine in Shenzen Municipality, HKU-SZH Fund for Shenzhen Key Medical Discipline.
Abstract (Originalsprache)
Background
Macrolide maintenance therapy (MMT) has demonstrated notable efficacy in reducing exacerbation in patients with bronchiectasis, which is a major risk factor for cardiovascular events. However, a comprehensive assessment of the cardiovascular benefits and safety profile of MMT in this population is lacking.
Methods
This territory-wide cohort study analysed patients diagnosed with bronchiectasis in Hong Kong between 2001 and 2018. Patients were classified as MMT receivers or macrolide non-receivers based on the administration of MMT. Propensity score (PS) matching was employed for confounding factors adjustment. The primary outcome of interest was major adverse cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction and stroke. The safety outcome was the occurrence of ventricular arrhythmias or sudden cardiac death. Cox proportional hazard regression analysis was utilised to compare the incidence of outcomes across the two groups.
Results
A total of 22 895 patients with bronchiectasis were identified. Following 1:2 PS matching, the final cohort consisted of 3137 individuals, with 1123 MMT receivers and 2014 macrolide non-receivers. MMT administration was associated with a significantly reduced risk of MACE (16.38 versus 24.11 events per 1000 person-years; hazard ratio (HR) 0.68, 95% CI 0.52–0.90). Importantly, the use of MMT was not associated with elevated risk of ventricular arrhythmias or sudden cardiac death (7.17 versus 7.67 events per 1000 person-years; HR 0.93, 95% CI 0.60–1.44).
Conclusions
The administration of MMT in patients with bronchiectasis was associated with a significant reduction in the risk of MACE, without any evidence suggesting an increased risk of severe arrhythmia-related adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, The University of Hong Kong Shen Zhen Hospital, Shen Zhen, China.
- Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong, China.
- Adult Cystic Fibrosis Centre, Liverpool Heart and Chest Hospital NHS Foundation Trust, Liverpool, UK.
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University, Liverpool Heart and Chest Hospital, Liverpool, UK.
- Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
- Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Tommaso Bucci, Christopher Tze-Wei Tsang, Freddy Frost
Förderung
- Sanming Project of Medicine in Shenzen Municipality
- HKU-SZH Fund for Shenzhen Key Medical Discipline
Zitieren
APA
Guo, R., Wat, D., Lam, S. H. M., Bucci, T., Tsang, C. T., Cai, A. P., Chan, Y. H., Ren, Q. W., Huang, J. Y., Zhang, J. N., Gu, W. L., Zhu, C. Y., Hung, Y. M., Frost, F., Lip, G. Y. H., & Yiu, K. H. (2025). Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis. European Respiratory Journal. https://doi.org/10.1183/13993003.01574-2024
Vancouver
Guo R, Wat D, Lam SHM, Bucci T, Tsang CT, Cai AP, et al. Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis. European Respiratory Journal. 2025. doi:10.1183/13993003.01574-2024
BibTeX
@article{Guo2025,
author = {Guo, Ran and Wat, Dennis and Lam, Steven Ho Man and Bucci, Tommaso and Tsang, Christopher Tze-Wei and Cai, An-Ping and Chan, Yap-Hang and Ren, Qing-Wen and Huang, Jia-Yi and Zhang, Jing-Nan and Gu, Wen-Li and Zhu, Ching-Yan and Hung, Yik-Ming and Frost, Freddy and Lip, Gregory Y H and Yiu, Kai-Hang},
title = {Cardiovascular benefits and safety profile of macrolide maintenance therapy in patients with bronchiectasis},
journal = {European Respiratory Journal},
year = {2025},
doi = {10.1183/13993003.01574-2024}
}
EUVIMED